Connection

CHAD CREIGHTON to Mice, Nude

This is a "connection" page, showing publications CHAD CREIGHTON has written about Mice, Nude.
Connection Strength

0.871
  1. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
    View in: PubMed
    Score: 0.065
  2. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 2006; 7(4):R28.
    View in: PubMed
    Score: 0.055
  3. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res. 2005 Mar; 3(3):119-29.
    View in: PubMed
    Score: 0.051
  4. Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
    View in: PubMed
    Score: 0.051
  5. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
    View in: PubMed
    Score: 0.039
  6. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
    View in: PubMed
    Score: 0.036
  7. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. J Clin Invest. 2019 03 01; 129(3):1015-1029.
    View in: PubMed
    Score: 0.033
  8. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nat Commun. 2018 07 16; 9(1):2732.
    View in: PubMed
    Score: 0.032
  9. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS One. 2018; 13(3):e0194913.
    View in: PubMed
    Score: 0.031
  10. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.031
  11. Coactivation of Estrogen Receptor and IKK? Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. Cancer Res. 2018 02 15; 78(4):974-984.
    View in: PubMed
    Score: 0.031
  12. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Res. 2017 07 01; 77(13):3502-3512.
    View in: PubMed
    Score: 0.030
  13. A genetic cell context-dependent role for ZEB1 in lung cancer. Nat Commun. 2016 07 26; 7:12231.
    View in: PubMed
    Score: 0.028
  14. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. 2016 Jan 25; 7:10500.
    View in: PubMed
    Score: 0.027
  15. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res. 2015 Dec 15; 75(24):5341-54.
    View in: PubMed
    Score: 0.027
  16. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.
    View in: PubMed
    Score: 0.026
  17. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.025
  18. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 2015 Jun 11; 34(24):3107-19.
    View in: PubMed
    Score: 0.025
  19. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2015 Mar 12; 34(11):1341-53.
    View in: PubMed
    Score: 0.024
  20. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.023
  21. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoS One. 2013; 8(5):e61747.
    View in: PubMed
    Score: 0.022
  22. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene. 2014 Feb 20; 33(8):1017-26.
    View in: PubMed
    Score: 0.022
  23. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013 Apr; 138(2):369-81.
    View in: PubMed
    Score: 0.022
  24. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
    View in: PubMed
    Score: 0.021
  25. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res. 2012 Jun 15; 18(12):3352-65.
    View in: PubMed
    Score: 0.021
  26. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.020
  27. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.019
  28. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009 May 29; 137(5):835-48.
    View in: PubMed
    Score: 0.017
  29. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.